Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: Abstracts of the 16th International Charles Heidelberger Symposium on Cancer Research

Open Access Oral presentation

JAKs and STATs in chemoresistance

Ana P Costa-Pereira

Author Affiliations

Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, London W12 0NN, UK

BMC Proceedings 2010, 4(Suppl 2):O15  doi:10.1186/1753-6561-4-S2-O15

The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1753-6561/4/S2/O15


Published:24 September 2010

© 2010 Costa-Pereira; licensee BioMed Central Ltd.

Oral presentation

Many cancer patients develop resistance to chemotherapeutic drugs and this results in elevated mortality. Understanding the mechanisms that mediate drug resistance is critical to develop novel therapeutic strategies. Fibroblast growth factor (FGF)-2, which leads to the formation of a B-RAF/PKCε/S6K2 multi-protein complex, plays a key role in chemoresistance. This enhances the selective translation of anti-apoptotic proteins such as BCL-2 and IAP family members and protects cells from death induced by chemotherapy in several cancer types. We have been investigating the role of Janus kinases (JAKs) and signal transducers and activators of transcription (STATs), most notably known for their pivotal roles in mediating cytokine and immune responses, in FGF-2-mediated chemoresistance. The participation of JAKs in drug resistance pathways and the implications of using inhibitors to these kinases in cancer multi-target therapies will be discussed.